Cerebral Aspergillosis, Invasive Aspergillosis
Conditions
Keywords
cerebral aspergillosis, isavuconazole
Brief summary
Study clinical context Cerebral aspergillosis (CA) is a rare location of invasive aspergillosis (IA), associated with a high morbidity and mortality. Since 2002, voriconazole is the recommended first line treatment of invasive aspergillosis. More recently, isavuconazole appeared to be not less effective than voriconazole in the treatment of filamentous IFI, with a better tolerance profile. The investigators aim to evaluate better the efficacy and the safety of isavuconazole in the treatment of cerebral aspergillosis by a descriptive, multicentric, international retrospective cohort study.
Interventions
None listed
Sponsors
Imagine Institute
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Proven or probable cerebral aspergillosis according to the EORTC criteria modified by adding diabetes in the host criteria * In child or adult * Treated by isavuconazole at least 7 days * Diagnosed between March 2017 and June 2020
Exclusion criteria
* Possible cerebral aspergillosis * isavuconazole treatment for less than 7 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Outcome of the patients : alive without CA treatment/alive under CA treatment/ deceased. | At baseline | Number of patients alive without CA treatment/alive under CA treatment/ deceased. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Monitoring of isavuconazole : dosage in the serum and in the cerebro-spinal-fluid | At baseline | dosage of isavuconazole in the serum and in the cerebro-spinal-fluid |
| -Adverse events under isavuconazole and drug interactions | At baseline | Adverse events under isavuconazole and drug interactions |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORFanny Lanternier, MD
Hôpital Necker
Outcome results
None listed